The Healthcare Associate will play an integral support role in analyzing new investment ideas in the fields of biotechnology and medical devices for a >$1B healthcare-dedicated investment vehicle. Specific activities will include building and maintaining market and company models, performing due diligence on healthcare companies and products via primary and secondary research, and maintaining proprietary firm databases. Over time, the position may also evolve into sourcing deals. The position provides an exceptional opportunity for individuals with healthcare backgrounds interested in gaining further experience in fundamental investment research applied to royalty and debt investing, and structuring these types of investments.

Major Responsibilities:

Develop and analyze financial models related to existing and potential future investments.
Perform due diligence on commercial stage products and companies.
Support investment documentation process.
Support sourcing efforts for new investments.

Required Skills and Experience:

2-5 years of finance experience in equity research, investment banking, corporate finance, management consulting, and/or investment management. The candidate preferably has a good knowledge of the pharmaceutical and/or medical device industries.
Exceptional financial modeling skills with attention to detail.
Motivated to learn the investing business.
Organized, detailed-oriented personality.
Impeccable integrity, work ethic and commitment.
Ability to work alone and without immediate supervision at times.
Demonstrated competence in biology, biochemistry, chemistry, or other scientific discipline.
Bachelor’s degree or greater from a top academic institution.

The Company:

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has invested approximately $780 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders.

The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.